GLP-1s Move to Front of Line in Obesity Care, According to Cardiologists

The American College of Cardiology has released new clinical guidance that positions GLP-1 medications like semaglutide and tirzepatide as a first-line option for treating obesity—without requiring prior failed attempts at diet and exercise. With cardiovascular risk reduction now a central goal, this shift may influence how the fitness industry supports members using medical weight-loss therapies.